Kymera Therapeutics (NASDAQ:KYMR) Price Target Cut to $134.00 by Analysts at BTIG Research

Kymera Therapeutics (NASDAQ:KYMR) had its target price reduced by BTIG Research from $138.00 to $134.00 in a research report released on Thursday,Benzinga reports. They currently have a buy rating on the stock.

Other analysts have also issued research reports about the company. Jefferies Financial Group upped their target price on Kymera Therapeutics from $73.00 to $122.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Citigroup upped their price objective on Kymera Therapeutics from $80.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Mizuho lifted their target price on Kymera Therapeutics from $81.00 to $120.00 and gave the company an “outperform” rating in a research note on Thursday, December 11th. JPMorgan Chase & Co. boosted their target price on shares of Kymera Therapeutics from $70.00 to $125.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Finally, Stifel Nicolaus set a $114.00 price target on shares of Kymera Therapeutics in a report on Monday, December 8th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $117.60.

Kymera Therapeutics Stock Performance

NASDAQ KYMR opened at $95.03 on Thursday. Kymera Therapeutics has a one year low of $19.44 and a one year high of $103.00. The company has a market capitalization of $6.84 billion, a price-to-earnings ratio of -26.47 and a beta of 2.21. The company’s 50-day simple moving average is $78.37 and its two-hundred day simple moving average is $64.89.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The business had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%.Kymera Therapeutics’s revenue for the quarter was down 60.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.88) EPS. Equities analysts expect that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In other news, Director Bros. Advisors Lp Baker bought 2,005,813 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The stock was purchased at an average price of $86.00 per share, with a total value of $172,499,918.00. Following the completion of the acquisition, the director directly owned 7,955,916 shares of the company’s stock, valued at $684,208,776. This trade represents a 33.71% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $89.76, for a total value of $448,800.00. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 450,895 shares of company stock valued at $40,486,151. 16.01% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Baker BROS. Advisors LP boosted its holdings in Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after purchasing an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC lifted its holdings in shares of Kymera Therapeutics by 17.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after buying an additional 1,124,747 shares during the period. Vanguard Group Inc. boosted its stake in shares of Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after buying an additional 845,922 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Kymera Therapeutics by 20.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after buying an additional 1,061,957 shares during the last quarter. Finally, BVF Inc. IL grew its holdings in Kymera Therapeutics by 6.6% during the second quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock worth $240,138,000 after acquiring an additional 340,909 shares during the period.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target to $140 and reaffirmed an “overweight” rating, signaling strong analyst confidence and implying meaningful upside from current levels. Piper Sandler Raise
• Neutral Sentiment: BTIG trimmed its target slightly from $138 to $134 but kept a “buy” rating — a modest adjustment that maintains institutional support but is not a bearish signal. BTIG Note
• Negative Sentiment: Kymera reported Q4 EPS of ($0.97), missing consensus (loss of $0.77) and posted revenue of $2.87M versus estimates near $14.8M; revenue fell ~60.8% year‑over‑year — a material earnings and top-line miss that increases short-term execution risk. Q4 Results
• Negative Sentiment: CEO Nello Mainolfi sold 30,000 shares for ~$2.71M (filed with the SEC). Insider sales can be interpreted negatively by some investors even though the CEO retains a large stake. Insider Sale
• Neutral Sentiment: Technical/contextual note: the stock is trading well above its 50‑ and 200‑day moving averages and near its 52‑week high, reflecting strong momentum that may amplify both positive analyst headlines and headline-driven volatility.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.